Abstract Library

#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?

Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liberini V

Authors: Liberini V, Rampado O, Gallio E, De Santi B, Ceci F,

Keywords: radiomic, PRRT, NET, SSTR-RADS, NETPET grade, RECIST 1.1 criteria, 68Ga-DOTATOC PET/CT, tumor/spleen ratio, radiomic analysis of 68Ga-DOTATOC PET/CT, radiomic features,

#2962 90Y- and/or 177Lu-DOTATOC Re-Challenge in Patients with Progressive Neuroendocrine Tumors

Introduction: Most patients treated with PRRT will eventually progress. Previous studies indicated that repeated PRRT is feasible and promising.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Aberle S

Authors: Aberle S, Benz M, Grokovski R, Christ E, Nicolas G,

Keywords: PRRT, Re-challenge, 90Y-DOTATOC, 177Lu-DOTATOC, neuroendocrine tumor,

#2863 Introduction of Dosimetry on PRRT Practice. A Useful Tool to Detect Responders and Evaluate Treatment Safety

Introduction: PRRT is a recognized salvage option for G1-G2 GEPNET. Currently, the Italian protocol (Lutathera AIFA Guidelines) consists in four fixed-dose of 177 Lu-DOTATATE. The dosimetry has recently been recognized as an important tool to guide PRRT but is not yet part of routine practice.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: SCALORBI F

Authors: Scalorbi F, Mazzaglia S, Maccauro M, Chiesa C, Prinzi N,

Keywords: prrt, healthy tissue and target lesion dosimetry, gastroenteropancreatic neuroendocrine tumor,

#1944 Predictive Value of Baseline Hematology Parameters on Outcome of 177Lu-DOTATOC PRRT

Introduction: In external beam radiotherapy it has been well established that improved tissue O2 increases therapy efficacy, likely mediated by O2 derived free radicals. Additionally, emerging evidence suggests immuno-stimulatory effects of radiotherapy through activation of lymphocytes.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kluge A

Authors: Kluge A, Baum R, Kulkarni H, Niepsch K, Bitterlich N,

Keywords: PRRT, hematology, prognosis, 177Lu-DOTATOC,

#1808 Lanreotide Autogel/Depot (LAN) in Combination with Peptide Receptor Radionuclide Therapy (PRRT) in Progressive Digestive and Lung Neuroendocrine Tumours (NETs): Design of the PRELUDE Study

Introduction: PRRT has potential to control progressive NETs and has been used in combination with somatostatin analogues such as LAN.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Prasad V, Truong Thanh X, Houchard A, Bodei L,

Keywords: PRRT, lanreotide,